Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Autor:	Gaia Gallo, J. Weisman, M. McKean-Matthews, Kyoungah See, Peter Foley, C.C. Bertram, Joseph F. Merola, Caitriona Ryan, Russel Burge, Lyn Guenther
Rok vydání:	2021
Předmět:	Health related quality of life Moderate to severe medicine.medical_specialty Adult patients business.industry Phases of clinical research Dermatology medicine.disease Placebo Ixekizumab Infectious Diseases Psoriasis Internal medicine medicine Sex organ business
Zdroj:	Journal of the European Academy of Dermatology and Venereology. 36
ISSN:	1468-3083 0926-9959
DOI:	10.1111/jdv.17836
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4bf7a87c996345fdfb258d8265f24fe6 https://doi.org/10.1111/jdv.17836 Zobrazit plný text záznamu Plný text